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Abstract
Background: Pathogenic BRCA1 founder mutations (c.4035delA, c.5266dupC) contribute to 3.77% of all consecutive
primary breast cancers and 9.9% of all consecutive primary ovarian cancers. Identifying germline pathogenic gene
variants in patients with primary breast and ovarian cancer could significantly impact the medical management of
patients. The aim of the study was to evaluate the rate of pathogenic mutations in the 26 breast and ovarian
cancer susceptibility genes in patients who meet the criteria for BRCA1/2 testing and to compare the accuracy of
different selection criteria for second-line testing in a founder population.
Methods: Fifteen female probands and 1 male proband that met National Comprehensive Cancer Network (NCCN)
criteria for BRCA1/2 testing were included in the study and underwent 26-gene panel testing. Fourteen probands
had breast cancer, one proband had ovarian cancer, and one proband had both breast and ovarian cancer. In a 26-
gene panel, the following breast and/or ovarian cancer susceptibility genes were included: ATM, BARD1, BLM, BRCA1,
BRCA2, BRIP1, CDH1, CHEK2, EPCAM, FAM175A, MEN1, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, PTEN,
RAD50, RAD51C, RAD51D, STK11, TP53, and XRCC2. All patients previously tested negative for BRCA1 founder
mutations.
Results: In 44% (7 out of 16) of tested probands, pathogenic mutations were identified. Six probands carried
pathogenic mutations in BRCA1, and one proband carried pathogenic mutations in BRCA2. In patients, a variant of
uncertain significance was found in BRCA2, RAD50, MRE11A and CDH1. The Manchester scoring system showed a
high accuracy (87.5%), high sensitivity (85.7%) and high specificity (88.9%) for the prediction of pathogenic non-
founder BRCA1/2 mutations.
Conclusion: A relatively high incidence of pathogenic non-founder BRCA1/2 mutations was observed in a founder
population. The Manchester scoring system predicted the probability of non-founder pathogenic mutations with
high accuracy.
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Background
Hereditary breast cancers account for approximately
10% of all breast cancers, and approximately 23% of all
ovarian cancers are considered hereditary [1, 2]. Accord-
ing to Plakhins et al., BRCA1 pathogenic founder muta-
tions (c.4035delA, c.5266dupC) contribute to 3.77% of all
consecutive primary breast cancers and 9.9% of all con-
secutive primary ovarian cancers [3]. BRCA1 and BRCA2
pathogenic founder mutation analysis is a relatively
straightforward and cost-effective screening strategy to
identify mutation carriers [4]. In Latvia, all consecutive
breast and ovarian cancer cases are eligible for BRCA1
pathogenic founder mutations (c.181 T >G, c.4035delA,
c.5266dupC) screening [5], and the costs of the test are
covered by the public health care system. However, ac-
cording to recent studies, non-founder BRCA1 and
BRCA2 pathogenic mutations account for up to 21.6% of
all BRCA1 and BRCA2 pathogenic mutations in the Asch-
kenazi Jewish population [6, 7]. There is little information
about pathogenic BRCA1/2 non-founder mutations in
Latvia. In a study published by Berzina et al., pathogenic
non-founder mutations in BRCA1 and BRCA2 were iden-
tified in 4 out of 30 high-risk breast/ovarian cancer fam-
ilies from the Latvian population [8]. In another study
published by Tihomirova et al., non-founder pathogenic
mutations in BRCA1 and BRCA2 were detected in 9 out
of 160 patients with breast and ovarian cancer [5]. These
findings suggest that the proportion of pathogenic
BRCA1/2 non-founder mutations is small and that family
cancer history alone is of limited value to find subgroups
of individuals, where expensive complete BRCA1/2 testing
is indicated.
The remaining hereditary breast and ovarian cancer
cases are associated with mutations in other breast and
ovarian cancer susceptibility genes, such as BRCA1/2,
TP53, PTEN, CDH1, STK11, MLH1, MSH2, MSH6, PMS2,
PALB2, CHEK2, ATM, RAD51C, RAD51D, BRIP1 and
other [9]. Patients and their relatives harbouring muta-
tions in hereditary cancer predisposing genes could bene
fit prevention and screening strategies or novel thera-
peutic approaches [10, 11]. Advances in next-generation
sequencing allowed the implementation of low-cost
multi-gene panel testing in clinical practice to detect
pathogenic mutations in hereditary cancer predisposing
genes [12].
Therefore, knowledge of the frequency and phenotyp-
ical features of pathogenic mutations beyond BRCA1
pathogenic founder mutations in breast and ovarian
cancer susceptibility genes is essential for determining
the role of second-line testing with multi-gene panels in
counselling unsolved high-risk breast and ovarian cancer
patients.
The aim of the study was to evaluate the rate of patho-
genic mutations in the 26 breast and ovarian cancer
susceptibility genes in patients who meet the criteria for
BRCA1/2 testing and to compare the accuracy of differ-




Sixteen sequential patients with primary breast and/or
ovarian cancer who met all inclusion criteria were in-
cluded in the study between October 2016 and August
2017. The inclusion criteria were as follows: 1) fulfil at
least one of the National Comprehensive Cancer net
work (NCCN) BRCA1/2 testing criteria (Table 1)
(www.nccn.org); 2) previously tested negative for
BRCA1 pathogenic founder mutations (c.181 T > G,
c.4035delA, c.5266dupC); 3) able to cover the cost of
the 26 multi-gene tests.
The following clinical information was obtained: age at
testing, personal cancer history, age at cancer diagnosis,
breast and/or ovarian cancer pathology, BRCA1/2 testing
history, a family cancer history that covers a 3-generation
pedigree according to probands information. The median
patient age was 45.6 years (33–63 years). Fifteen out of 16
(93.75%) patients were females, and 1 out of 16 (6.25%)
patients was male. Thirteen patients had unilateral breast
cancer, 1 patient had bilateral breast cancer, 1 patient had
ovarian cancer, and in 1 patient had both breast and ovar-
ian cancer. Four out of 16 (25%) breast cancers were
luminal-like HER2 negative, 2 out of 16 (12.5%) breast
cancers were luminal B HER2 positive, 8 out of 16 (50%)
breast cancers were triple-negative, and 1 out of 16
(6.25%) breast cancers was HER2 positive. The patient
characteristics are summarized in Table 2.
DNA testing
Informed consent for genetic testing was obtained for all
patients. All patients underwent DNA testing with a
26-gene panel (myBRCA HiRisk Hereditary Breast and
Table 1 NCCN selection criteria for screening of mutations in
BRCA1and BRCA2
At least one of the following criteria has to be met:
1. Personal history of breast cancer diagnosed < age 45 years
2. Personal history of breast cancer diagnosed < age 50 years and at
least one case of breast cancer at any age in close blood relative
3. Personal history of triple negative breast cancer diagnosed < age
60 years
4. Personal history of breast cancer diagnosed at any age and at least
two cases of breast cancer diagnosed at any age or at least one close
blood relative with breast cancer diagnosed ≤50 years or at least one
blood relative with ovarian carcinoma or a close male blood relative
with breast cancer
5. Personal history of ovarian cancer
6. Personal history of male breast cancer
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Ovarian Cancer screening Test, VeritasGenetics, USA)
that is a targeted next-generation sequencing assay for
the detection of mutations in 26 breast and ovarian cancer
susceptibility genes. The genes included high-penetrance
breast-ovarian genes (BRCA1, BRCA2, PTEN, TP53,
CDH1, STK11, PALB2), moderate-penetrance breast and/
or ovarian genes (CHEK2, BRIP1, ATM), and additional
genes (BARD1, BLM, EPCAM, RAD50, RAD51C, RAD51D,
MEN1, MRE11A, MUTYH MSH2, MLH1, NBN, MSH6,
PMS2, FAM175A, XRCC2). In all patients, the test was per-
formed using saliva. The specificity and sensitivity of the
assay are 99.9% for point mutations and small insertions/
deletions in the 24 sequenced genes and 99.9% for struc-
tural variations in BRCA1 and BRCA2.
Statistical analysis
The specificity, sensitivity and accuracy of the NCCN
criteria, Manchester scoring system and Swedish Breast
cancer group criteria for the prediction of pathogenic
non-founder mutations were evaluated. The Manchester
score of 15 points threshold was used to assess the likeli-
hood of BRCA1/2 pathogenic mutation [13]. The specifi
city, sensitivity and accuracy of different selection cri-
teria for BRCA1/2 testing in our cohort were calculated
using MedCalc Statistical Software version 17.9.
Results
In seven out of sixteen (44%) patients included, patho-
genic non-founder BRCA1/2 mutations were identified.
Six patients carried pathogenic variants of BRCA1 and
one of BRCA2. In four patients, variants of uncertain sig-
nificance of BRCA2, RAD50, MRE11A and CDH1 were
found. Detailed results are shown in Table 3. The NCCN
criteria showed a high sensitivity (100%) with low specifi-
city (50%) for the prediction of non-founder pathogenic
BRCA1/2 mutations. The Swedish Breast cancer group
criteria showed a low sensitivity (57.1%) with three false
negative results. The Manchester scoring system showed a
high accuracy (87.5%) for the prediction of pathogenic
non-founder BRCA1/2 mutations with high sensitivity
(85.7%) and specificity (88.9%). The sensitivity, specificity
and accuracy of different criteria/scoring systems for the
detection of probability of BRCA1/2 pathogenic mutations
in our cohort are compared in Table 4.
Discussion
Our study is the first report on the use of a 26 gene
panel in to examine breast and ovarian cancer suscepti-
bility genes in patients in Latvia. We demonstrated a
high frequency of pathogenic non-founder germline mu-
tations in BRCA1 and BRCA2 genes. In seven out of six-
teen (44%) primary breast and ovarian cancer patients
Table 2 The baseline characteristics of patient group











1 54 Breast Ductal Luminal missing Mother and maternal aunt – breast cancer age 60; daughter -
polycytemia vera age15, brother – melanoma age 60
2 40 Breast Ductal Triple-negative* G3 Mother - Breast and ovarian cancer age 40




G3/G3 Paternal grandmother - unknown primary gynecological
cancer age 50
4 63 Breast and Ovaries Ductal Triple-negative G2 Mother with breast cancer age 55; sister - ovarian cancer
age 59
5 37 Ovaries NA NA NA Mother - breast cancer age 64
6 58 Breast Lobular Luminal G2 Mother and maternal aunt – breast cancer age > 60
7 43 Breast Ductal Triple-negative G3 No
8 42 Breast Ductal/
Medullary
Triple-negative G2 Mother - breast cancer age 60
9 50 Breast Ductal Triple-negative G3 Mother - breast cancer age 52
10 35 Breast Ductal Triple-negative G3 Mother - breast cancer age 46
11 52 Breast Ductal Luminal B HER2
positive
G2 Mother and maternal aunt – breast cancer age > 50
12 41 Breast Ductal HER2 positive G3 No
13 53 Breast Ductal Triple-negative missing No
14 36 Breast Ductal Luminal missing No
15 53 Breast Ductal Luminal missing Mother and maternal grandmother – breast cancer
age > 60 years
16 40 Breast Ductal Luminal B HER2
positive
missing No
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matching the criteria for BRCA1/2 testing pathogenic
non-founder BRCA1/2 mutations were identified. All 7
pathogenic mutations, including 2 large deletions, are
novel in populations of Latvia [5, 8]. These results may
suggest that the present practice of testing only the 3
most frequent BRCA1 pathogenic founder mutations is
insufficient and fails to detect a considerable number of
pathogenic mutations in BRCA1/2. However, our study
comprises a relatively small cohort of selected patients. In
a study published by Frank et al., 21.6% of patients with
Ashkenazi ancestry pathogenic non-founder BRCA1 and
BRCA2 mutations were identified [6]. In contrast, in the
Finnish population of high-risk individuals tested negative
for 28 BRCA1/2 pathogenic founder mutations, additional
pathogenic mutations in BRCA1 and BRCA2 accounted
for just 1.2% [12]. Much larger numbers are necessary to
assess the real proportion of pathogenic non-founder mu-
tations in the population of Latvia.
Despite the drawbacks of such a small study group,
the initial results raised some observations.
Interestingly, probands that carried a pathogenic
non-founder mutation had some common features. All six
breast cancer patients in our study with proven pathogenic
non-founder BRCA1/2 mutations had a triple-negative
phenotype. It is well established that approximately 80% of
all BRCA1/2– related tumours have a triple-negative
phenotype [14–18]. The prevalence of pathogenic germline
BRCA1/2 mutations in the selected triple-negative breast
cancer patients ranged from 9.2 to 34.4% [19–22]. Additio
nal analyses of cDNA microarray data from van’t
Veer showed that BRCA1-related tumours have a
sporadic basal-like breast cancer gene expression pro-
file [23]. Additionally, according to Richardson et al.,
loss of BRCA1 function could play a role in the de-
velopment of basal-like breast cancers [24]. Couch et
al. identified BRCA1/2 pathogenic mutations in 11.2% of
triple-negative breast cancer patients and other
breast-ovarian cancer predisposing gene mutations in
3.7% of triple-negative breast cancer patients [25].
In our study we used the NCCN criteria for screening
pathogenic mutations in BRCA1 and BRCA2, where
triple-negative breast cancer is used as a criterion to-
gether with an age limit < 60. Only one out of six breast
cancer patients in our study who carried a pathogenic
BRCA1/2 non-founder mutation was older than 60 years
of age, but in this case, family cancer history was positive
in the study published by Couch et al., 3.1% of
triple-negative breast cancer patients older than 60 years
and only 1.4% with no family history of breast or ovarian
Table 3 Results






Swedish Breast cancer group criteria for screening of
mutation in BRCA1 and BRCA2
1 RAD50c.980G > A VUS NCCN4 17 One case of male breast cancer
2 BRCA1c.5075-?_5152
+?del
PAT NCCN2 29 One case of triple-negative breast cancer ≤age 40
3 BRCA1c.1-?_c.134 +?del PAT NCCN3 20 One case of breast cancer ≤age 35
4 BRCA2c.6998dupT PAT NCCN4 19 Breast cancer and ovarian cancer in one individual.
5 BRCA1c.5117G > A PAT NCCN5 15 Do not match
6 RAD50c.251 T > A VUS NCCN4
MRE11Ac.1715G > A VUS 6 NA
7 BRCA1c.1961delA PAT NCCN3 14 Do not match
8 BRCA2c.280C > T VUS NCCN4 14 Do not match
9 BRCA1c.5117G > A PAT NCCN4 16 Do not match
10 BRCA1c.4996_4997dupTA PAT NCCN4 20 One case of triple-negative breast cancer ≤age 40
11 Negative Negative NCCN4 2 Do not match
12 Negative Negative NCCN1 2 Do not match
13 Negative Negative NCCN3 8 Do not match
14 Negative Negative NCCN1 8 Do not match
15 CDH1 c.808 T > G VUS NCCN4 8 Do not match
16 Negative Negative NCCN1 0 Do not match
PAT, pathological; VUS, variant of uncertain significance; *Triple-negative breast cancer was defined as ER-0%; PR-0%; HER2- negative;
Table 4 Comparison of different selection criteria for BRCA1/2
testing in our cohort
Criteria Sensitivity Specificity Accuracy
NCCN 100% 50% 64%
Manchester scoring system 85.7% 88.9% 87.5%
Swedish Breast cancer group 57.1% 88.9% 75%
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cancer were diagnosed with BRCA1/2 pathogenic muta-
tion [25]. Therefore, our study results support the current
NCCN guidelines for screening all triple-negative breast
cancer patients younger than 60 years of age.
In contrast, the application of the upper age limit for
triple-negative breast cancer patients of 40 years (Swedish
Breast cancer group criteria for screening for mutations in
BRCA1 and BRCA2) would miss several BRCA-positive
cases in our cohort [26].
Our small study showed the high accuracy of the
Manchester scoring system for the prediction of
pathogenic non-founder BRCA1/2 mutations in founder
mutation-negative patients. Our finding is supported by
several other studies performed on the validation of the
Manchester scoring system in populations of UK,
Germany and South East Asia [13, 27, 28]. However,
larger numbers of cases are needed for comprehensive
validation of these criteria in the population of Latvia.
Additionally, three out of eight patients tested negative
for 26 breast and ovarian cancer susceptibility genes were
HER2 positive. According to a recently published study,
only 9% of BRCA1-related breast tumours and 13% of
BRCA2-related breast tumours were HER2 positive [29].
HER2 positivity is also included in the Manchester scoring
system as a BRCA1/2 probability decreasing factor [13].
Ovarian cancer in a personal or family history was docu-
mented in three out of seven patients who carried a
pathogenic BRCA1/2 non-founder mutation. Additionally,
in one case, unknown gynaecological cancer was reported
in a paternal aunt. According to recent studies, the
presence of ovarian cancer in personal or family history of
pathogenic BRCA1 founder-negative breast cancer
patients increases the possibility of carrying previously
undetected pathogenic BRCA1/2 non-founder mutations
[30, 31]. Recently, in a study published by Couch et al.,
ovarian cancer in family history was documented only in 1
of 54 pathogenic non-BRCA1/2 mutation carriers with
triple-negative breast cancer [25].
In our study, no pathogenic mutations were detected in
another 24 genes included in the panel. Some previously
published studies demonstrated that the rate of patho-
genic mutations in non-BRCA1/2 genes ranged from 2.9
to 9.3% [32–35].
Four of the 16 (25%) patients were identified to have a
variant of unknown significance (VUS) in BRCA2, RAD50,
CDH1 and MRE11. Unfortunately, due to an insufficient
sample size in our study, we cannot elaborate upon those
results.
Conclusion
A relatively high incidence of pathogenic non-founder
BRCA1/2 mutations was observed among patients with
triple-negative familial breast cancer in a founder popu-
lation. The Manchester scoring system predicted the
probability of non-founder pathogenic mutations with
high accuracy.
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